Business Wire

Oral-B and Straumann Partner on a Landmark Alliance for Scientific Education to Improve the Periodontal and Peri-Implant Health of Patients Worldwide

Share

Oral-B and Straumann, two of the world’s leading oral care companies, are proud to announce a new global alliance whose purpose is to elevate the importance of prevention in periodontal and peri-implant health. The alliance will set new standards in quality scientific education for dental professionals and help their patients achieve better long-term outcomes.

The Oral-B Straumann alliance has a long-term goal of delivering a holistic program of scientific events, professional courses, webinars and publications, co-created with and delivered by the world’s leading experts and thought leaders in dentistry.

The alliance will be launched on 17th June 2022 with a Sponsored Scientific Session at EuroPerio10 Copenhagen – the world’s leading congress in periodontology and implant dentistry – where both companies will also present their recent innovations for periodontal and peri-implant patients: Straumann Biomaterials solutions ranging from enhanced wound healing and bone regeneration to soft-tissue management and wound care and Oral-B iO Specialized Clean brush head, Oral-B iO10 & iOsense to empower patients in effective self-care.

“As patients around the world invest in dental implants, they need to recognize that self-care around implants is just as important as around their natural teeth. The Oral-B/Straumann Alliance will play an important role in enabling ongoing dialogue between dental professionals and their patients so both understand the most up to date science on prevention of implant-related diseases and promotion of periodontal health,” says J. Leslie Winston, Vice President, Global Health Care R&D, Procter & Gamble.

Arik Zucker, Vice President, Global Head of Biomaterials, Straumann Group, adds: “Prevention of tooth or implant loss is for many years an important topic for us in the Straumann Group. As one of the world’s leading dental implant companies, we work closely with experts from the research and clinical fields to address the issues caused by peri-implantitis and periodontitis. The Alliance with Oral-B complements our efforts and offers a solid ground for further scientific and educational activities that will enable more dental professionals to improve their patients’ lives.”

Oral-B & Straumann Alliance: Partnering to Amplify the Importance of Prevention

The vision for the Oral-B Straumann Alliance is ambitious: an unwavering commitment to amplifying the importance of prevention through scientific education, helping dental professionals and their implant and periodontal patients achieve better outcomes.

Starting with the Sponsored Scientific Session at Europerio10 in Copenhagen on 17th June 2022, the alliance will be rolled out over a series of scientific exchange activities that include a forthcoming scientific symposium at the American Academy of Periodontology annual meeting in October 2022, as well as continuing education courses, webinars and publications- all developed with and delivered by the world’s leading experts and thought leaders- focusing on the importance of preventive clinical and self-care for the life cycle of the implant and general periodontal health.

The Sponsored Scientific Session “Limiting periodontal and peri-implant diseases during and beyond the pandemic: from the chair to self-care.” will be presented at Europerio10 by Dr. Martina Stefanini (University of Bologna), Prof Giorgio Pagni (University of Milan) and Prof Filippo Graziani (University of Pisa). Reflecting on the importance and potential impact of the Oral-B Straumann alliance, Prof Graziani remarked: “I strongly believe that with the changes in the society and patients’ behaviors it is fundamental to provide a large array of solutions for general health. There are so many opportunities that any patient may get confused by the plethora of products and indications. Thus, this alliance should be cherished in order to simplify the life of our patients and provide additional benefits for their health.”

Periodontal Disease: the #1 cause of tooth loss

Tooth loss is a major global oral health concern: 69 % of 35-44-year-olds in the US have lost at least one permanent tooth1 while in Europe 30 % of 65-74-year-olds have no natural teeth left2. With periodontal disease being the number one cause of tooth loss in adults-and prevalent in up to 50 % of the global adult population- its impacts can have a detrimental effect on the quality of a patient’s life, with a growing volume of scientific evidence that consistently highlights the association between periodontal disease and a number of systemic conditions, such as Type 2 diabetes, cardiovascular disease and Alzheimer’s disease.3

The economic impacts of periodontal disease (both on the individual and society as a whole) are no less significant: A single tooth implant costs 2,000-5,000 euros and to protect their investment, patients must be educated on how to remove plaque (the dominant risk factor for oral disease) and prevent periodontal & peri-implant diseases, with dental professionals playing a central role in this process.

Prevention Pays Off

Studies show that the removal of 80-85 % of oral biofilm twice a day as part of a patient’s self-care routine can maintain oral and implant health.4 And as we emerge from the pandemic prevention of periodontal disease is more important now than ever, with recent research finding that Covid-19 patients with periodontitis are 3.5x more likely to be admitted to intensive care and 9x more likely to die than Covid-19 patients with healthy gums.5 Beyond the significant personal benefit to the patient, recent studies have also shown that eliminating the burden of gingivitis and increasing the diagnosis and treatment rate of periodontitis to 90% in 6 European countries shows a positive return on investment for society over a 10-year period.6

Trusted Science, Trusted Brands, Indispensable Partners for Dental Professionals

Both Oral-B & Straumann are innovation leaders in their respective fields: the former with its range of proven personal oral hygiene products the #1 dentist recommended brand worldwide and the latter as the world-leading brand for confidence in esthetic dentistry and a gold standard in implantology. With their extensive portfolios of breakthrough oral care products and biomaterials, Oral-B and Straumann will support the launch of the alliance by presenting to dental professionals an upcoming range of new innovations for successful patient outcomes:

Oral-B iO Specialized Clean Brush Head: Brushing personalized to the needs of Implant Patients

The highly anticipated Specialized Clean brush head with its distinctive bristle field designed with dental professionals exclusively for the Oral-B iO series of electric rechargeable toothbrushes combines oscillation-rotation with the gentle energy of microvibrations to effectively reach and clean around implant restorations and other hard-to-reach areas that require special focus.

Findings from a recent case study of implant patients who used the Oral-B iO9 round brush heads together with the Specialized Clean brush head showed a 62.7 % reduction in plaque 8 weeks after switching to iO from their regular toothbrush; in line with previously published research showing the superior oral hygiene benefits in favour of Oral-B iO versus a manual toothbrush. In a recent study, 3 times more patients with swollen gums who used Oral-B iO were categorized as generally healthy over an 8-week period compared to those patients using a manual toothbrush.7

Oral-B iO10 with iOsense: Technology for better self-care

Launching in September 2022, Oral-B iO10 with iOsense offers real-time coaching via Artificial Intelligence and the Oral-B app, making it even simpler to establish good oral hygiene habits without the need to bring your phone into the bathroom. The iOsense™ Smart Charger personalizes your clean with live coaching to guide how, when and where you brush by providing real-time feedback on your brushing via the LEDs built into the charger, ensuring the user brushes thoroughly, with optimal pressure and for the dental professional recommended duration.

Research shows a positive correlation between app usage and improved oral hygiene.8 And a recent analysis of 16.7 million anonymized real world brushing sessions using the Oral-B app and Oral-B® smart-connected oscillating-rotating toothbrushes found that real-time feedback using Position Detection resulted in:9

  • Excellent brushing thoroughness: with an average of 94% of brushing zones covered and with 8 out of 10 brushing sessions producing complete coverage.
  • Longer Brushing: Brushing sessions with real-time app feedback lasted on average 2m43s, 21.6 % longer than brushing sessions without the app and helping users ensure they brush for the dental professional recommended 2 minutes. With the average brushing session with a manual toothbrush reported to be just 46 seconds long there has never been a better time adopt interactive brush technology to help establish better brushing behaviors.

Straumann Biomaterials: proven technologies to help dental professionals set their patients up for success

Equally significant is the contribution to dentistry by Straumann, a global leader in the field of dental implants and an important player in the biomaterials market. Offering the industry’s most comprehensive biomaterials portfolio, Straumann provides dental professionals with a unique range in oral regeneration that covers a large range of indications, from enhanced wound healing and bone regeneration to soft-tissue management and wound care:

  • Straumann® Emdogain®: a unique gel containing enamel matrix derivative with an impressive scientifical background of over 1000 publications10, including multiple 10-year follow-up studies11, and over 25 years of clinical experience. Based on its success and thanks to a new, shorter, and thinner applicator, Emdogain® FL can now be applied by specialists, general practitioners, and dental hygienists in a flapless approach connected to the hygiene phase of the periodontal treatment.12
  • Jason® membrane – a pericardium-based collagen membrane with a long barrier function, tensile strength, and easy handling.13,14
  • Straumann® XenoGraft – an easy-to-handle bovine bone graft that provides long-term volume stability.
  • Labrida BioClean™ – a proven solution for effective debridement of teeth and dental implant surfaces as part of maintenance or treatment protocols provided by specialists, general practitioners, and even dental hygienists.15,16

About Oral-B®

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About The Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Dental Wings, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss. Headquartered in Basel, Switzerland, the Group currently employs more than 9000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

__________________________
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028797/#:~:text=Statistics%20provided%20by%20the%20American,of%20their%20permanent%20teeth6 (accessed April 2022)
2 https://www.euro.who.int/en/health-topics/disease-prevention/oral-health/data-and-statistics#:~:text=Dental%20caries%20and%20severe%20periodontal,cases%20per%20100%20000%20people (accessed April 2022)
3 https://www.scientificamerican.com/custom-media/a-scientific-approach-to-cleaning-your-mouth/ (accessed April 2022)
4 Wingrove S. Why personalized oral hygiene technology matters. Compend Contin Educ Dent. 2022;43(suppl 1):1-4
5 Marouf N, Cai W, Said KN, et al. Association between periodontitis and severity of COVID-19 infection: A case-control study. J Clin Periodontol 2021; 48(4): 483-91
6 Bouchard, Carner, Carter et al., Time to take gum disease seriously, The Economist Intelligence Unit, 2021
7 Grender J, Goyal CR, Qaqish J, Adam R. Int Dent J 2020 70 (Suppl 1) S7-S15
8 Tonetti, MS, Deng, K, Christiansen, A, et al.. J Clin Periodontol. 2020; 47: 1219– 1226.
9 Thurnay S, Adam R, Meyners M. Oral Health Prev Dent. 2022 Jan 20;20(1):1-10. doi: 10.3290/j.ohpd.b2572911. PMID: 35049247
10 According to PUBMED search for “Emdogain” or “enamel matrix derivative”
11 Sculean A, Kiss A, Miliauskaite A, Schwarz F, Arweiler NB, Hannig M. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. 2008 Sep;35(9):817-24
12 Graziani F, Gennai S, Petrini M, Bettini L, Tonetti M. Enamel matrix derivative stabilizes blood clot and improves clinical healing in deep pockets after flapless periodontal therapy: A Randomized Clinical Trial. J Clin Periodontol. 2019 Feb; 46(2):231-240.
13 Rothamel et al. 2012, Biocompatibility and Biodegradation of a Native, Porcine Pericardium Membrane. Results from in vitro/in vivo Examination, J. Int J Oral Maxillofac Implants, 27(1):146-54.
14 Barbeck et al. 2015, Porcine dermis and pericardium-based, non-cross-linked materials induce multinucleated giant cells after their in vivo implantation: A physiological reaction? J Oral Implantol., 41(6):e267-81.
15 Wohlfahrt JC, Aass AM, Koldsland OC: Treatment of peri-implant mucositis with a chitosan brush-A pilot randomized clinical trial. Int J Dent Hyg 2019;17:170-176.
16 Wohlfahrt JC, Evensen BJ, Zeza B, Jansson H, Pilloni A, Roos-Jansaker AM, Di Tanna GL, Aass AM, Klepp M, Koldsland OC: A novel non-surgical method for mild peri-implantitis- a multicenter consecutive case series. Int J Implant Dent 2017;3:38.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate:
Procter & Gamble GmbH, Sulzbacher Straße 40, 65824 Schwalbach am Taunus,
Boris Atlas
atlas.b@pg.com

Institut Straumann AG, Peter Merian-Weg 12, CH-4052 Basel, Switzerland
Laurentiu Motoc
laurentiu.motoc@straumann.com

Media:
MSL Germany, Otto-Messmer-Straße 1, 60314 Frankfurt am Main
Christina Meyer
christina.meyer@mslgroup.com

Procter & Gamble IO sa, 47 route de St-Georges, 1213 Petit Lancy, Switzerland
Paola Mulas
mulas.p@pg.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ganymed Robotics Raises €21M to Complete the Development of Its Next Generation Surgical Robot and Prepare for a Commercial Launch7.7.2022 09:00:00 EEST | Press release

Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, announced it has raised €21 million in the oversubscribed first close of its Series B funding. The round was led by Cathay Health, with participation of Credit Mutuel Innovation, Kurma Partners, BNP Paribas Développement and internationally renowned surgeons. The funding will be used to: - Support Ganymed’s expansion in France and in the United States; - Finalize the industrial development of its surgical robotic assistant for knee arthroplasty (TKA); - Accelerate regulatory and marketing developments across geographies; - Diversify the innovation product pipeline. Since inception in 2018, Ganymed Robotics has experienced a rapid growth. In collaboration with world-class clinicians, it has validated its proprietary algorithms and collected unique in vivo data via a 100-patient observational study, successfully completed functional prototype tests, initiated industrialization of

The Solidarity Transport Hub Company Starts Looking for a Financial Investor7.7.2022 09:00:00 EEST | Press release

The Solidarity Transport Hub company from Poland is starting the process of selecting a Financial Partner experienced in investments in the infrastructure industry to run a joint venture in the form of a special purpose vehicle subsidiary of the STH ("Airport Component SPV"). The company is waiting for applications from interested contractors until August the 26th 2022. Solidarity Transport Hub (STH) is the largest infrastructure investment in Poland, which consists of constructing the largest airport in the Central Europe region as well as developing ca. 2000 km of new railways countrywide. STH`s projects are financed from three sources: treasury securities, commercial financing, and funds from the European Union. – From the very beginning, we were prepared to propose cooperation to potential investors. We are a reliable and attractive partner for foreign investors in the wake of the need to build a large airport, which will become the main transfer hub in our part of Europe – says Mi

ADVA Optical Networking SE: ADVA Optical Networking SE to enter into negotiations for a domination agreement or domination and profit and loss transfer agreement with Acorn HoldCo, Inc.7.7.2022 01:15:00 EEST | Press release

Today, Acorn HoldCo, Inc. (“Acorn HoldCo”) has informed ADVA Optical Networking SE (“ADVA”) about its intention to enter into negotiations regarding the conclusion of a domination agreement (“DA”) or a domination and profit and loss transfer agreement (“DPLTA”, either the DA or the DPLTA the “Agreement”) within the meaning of Sec. 291 para. 1 of the German Stock Corporation Act (Aktiengesetz) with Acorn HoldCo (or a subsidiary yet to be established) as the dominating entity and ADVA as the dominated entity. ADVA’s management board has decided to enter into negotiations for such an Agreement. The necessary preparatory measures include obtaining a valuation memorandum and proposing a contract auditor to be appointed by the court. The decision for or against the conclusion of an Agreement will be taken at a later date following a comprehensive review in consultation and coordination with Acorn HoldCo’s management. To be effective, an Agreement will require the approval of ADVA’s general m

ADVA CEO Brian Protiva to step down, CTO Christoph Glingener appointed as successor6.7.2022 23:45:00 EEST | Press release

ADVA (FSE: ADV) today announced that Brian Protiva is to step down as CEO. After a transition period of several weeks, Protiva will assume the role of vice chairman of Acorn HoldCo, Inc. (the holding company of Adtran and ADVA). Christoph Glingener will be appointed ADVA’s new CEO and will also continue as the company’s CTO. During Protiva’s 25-year tenure as chief executive officer, he successfully steered the company from a small start-up to an industry leader in metro WDM and Ethernet access devices. As ADVA is about to complete its business combination with Adtran, Protiva will support the further unification of the companies over the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005829/en/ Brian Protiva, CEO, ADVA (Photo: Business Wire) “Working side-by-side with Brian for eight years, I was privileged to see one of the industry‘s true leaders develop a world-class company. During his 25 years as A

MSCI Schedules Earnings Call to Review Second Quarter 2022 Results6.7.2022 21:30:00 EEST | Press release

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today it will release its results for the second quarter 2022 on Tuesday, July 26, 2022, before the market opens. A copy of the earnings release, as well as an earnings presentation and a quarterly update, will be made available on MSCI's Investor Relations website. MSCI's senior management will review the second quarter 2022 results on Tuesday, July 26, 2022 at 11:00 AM Eastern Time. To listen to the live event via webcast, visit the events and presentations section of MSCI's Investor Relations website, https://ir.msci.com/events-and-presentations or to join via telephone, please register yourself at https://ir.msci.com/events-and-presentations. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including a dial-in number and a unique participant pin that can be used to access the c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom